TRCT
VIGL

Tower Research Capital (TRC)’s Vigil Neuroscience VIGL Stock Holding History

Tower Research Capital (TRC)’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,044
Closed -$5.42K – 5588
2025
Q1 		$5.42K Sell
3,044
-5,890
-66% -$13.2K ﹤0.01% 4124
2024
Q4 		$15.2K Buy
8,934
+5,422
+154% +$16K ﹤0.01% 3417
2024
Q3 		$11.9K Sell
3,512
-8,253
-70% -$30.6K ﹤0.01% 3633
2024
Q2 		$47.1K Buy
11,765
+5,976
+103% +$20.5K ﹤0.01% 3152
2024
Q1 		$19.7K Buy
5,789
+2,906
+101% +$9.07K ﹤0.01% 3013
2023
Q4 		$9.74K Buy
2,883
+532
+23% +$2.74K ﹤0.01% 4349
2023
Q3 		$12.7K Buy
2,351
+1,726
+276% +$11.9K ﹤0.01% 3877
2023
Q2 		$5.88K Sell
625
-857
-58% -$8.1K ﹤0.01% 4779
2023
Q1 		$15K Sell
1,482
-350
-19% -$3.94K ﹤0.01% 3825
2022
Q4 		$23K Buy
+1,832
New +$22.5K ﹤0.01% 3013
2022
Q2 		– Sell
-1,773
Closed -$12K – 6548
2022
Q1 		$12K Buy
+1,773
New +$23.4K ﹤0.01% 4104

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Tower Research Capital (TRC)'s VIGL Position: Q2 2025 in Review

Tower Research Capital (TRC) sold out of Vigil Neuroscience (VIGL) in Q2 2025, closing a stake of 3,044 shares — an estimated $5.42K sold.

Tower Research Capital (TRC) first reported a position in VIGL in Q1 2022 and held it in 11 quarters. The position peaked at $47.1K in Q2 2024. 78 funds tracked by Wall St. Rank hold VIGL as of Q2 2025.

  • Tower Research Capital (TRC) reported no remaining Vigil Neuroscience position as of Q2 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 3,044 Vigil Neuroscience shares in Q2 2025, an estimated $5.42K.
  • Tower Research Capital (TRC) first reported a position in Vigil Neuroscience in Q1 2022 and held it in 11 quarters.
  • Tower Research Capital (TRC)'s Vigil Neuroscience position peaked at $47.1K in Q2 2024.
  • 78 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q2 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.